Brokers

Brokers Offer Predictions for Fusion Pharmaceuticals Inc.’s Q2 2022 Earnings (NASDAQ:FUSN)


Fusion Pharmaceuticals Inc. (NASDAQ:FUSNGet Rating) – Stock analysts at B. Riley issued their Q2 2022 earnings per share estimates for Fusion Pharmaceuticals in a research note issued to investors on Wednesday, May 11th. B. Riley analyst J. Walsh expects that the company will earn ($0.49) per share for the quarter. B. Riley also issued estimates for Fusion Pharmaceuticals’ Q3 2022 earnings at ($0.49) EPS, Q4 2022 earnings at ($0.50) EPS, FY2022 earnings at ($1.95) EPS, FY2023 earnings at ($1.69) EPS, FY2024 earnings at ($1.60) EPS, FY2025 earnings at ($1.70) EPS and FY2026 earnings at ($1.68) EPS.

Several other research firms have also issued reports on FUSN. Zacks Investment Research lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 20th. Wedbush decreased their price target on shares of Fusion Pharmaceuticals from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. Finally, Brookline Capital Management restated a “buy” rating on shares of Fusion Pharmaceuticals in a research report on Wednesday, February 2nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $15.31.

NASDAQ FUSN opened at $4.00 on Monday. The firm has a market capitalization of $173.37 million, a PE ratio of -2.06 and a beta of -0.66. Fusion Pharmaceuticals has a 12 month low of $3.71 and a 12 month high of $10.40. The company’s 50 day simple moving average is $6.40 and its 200 day simple moving average is $6.43.

Fusion Pharmaceuticals (NASDAQ:FUSNGet Rating) last posted its quarterly earnings data on Thursday, March 17th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.07. Fusion Pharmaceuticals had a negative net margin of 4,119.85% and a negative return on equity of 34.87%. The business had revenue of $0.59 million for the quarter.

In other Fusion Pharmaceuticals news, CEO John Valliant sold 4,100 shares of Fusion Pharmaceuticals stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $7.85, for a total transaction of $32,185.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 70,834 shares of company stock worth $517,192. Corporate insiders own 6.12% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. grew its position in Fusion Pharmaceuticals by 94.1% during the 1st quarter. Federated Hermes Inc. now owns 3,055,037 shares of the company’s stock worth $23,738,000 after purchasing an additional 1,481,037 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Fusion Pharmaceuticals during the 4th quarter valued at $417,000. Woodline Partners LP boosted its stake in shares of Fusion Pharmaceuticals by 57.4% during the 4th quarter. Woodline Partners LP now owns 243,340 shares of the company’s stock valued at $1,015,000 after buying an additional 88,719 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of Fusion Pharmaceuticals by 22.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,048,956 shares of the company’s stock valued at $4,374,000 after buying an additional 190,944 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Fusion Pharmaceuticals during the 3rd quarter valued at $213,000. Hedge funds and other institutional investors own 64.25% of the company’s stock.

About Fusion Pharmaceuticals (Get Rating)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors.

See Also

Earnings History and Estimates for Fusion Pharmaceuticals (NASDAQ:FUSN)



Receive News & Ratings for Fusion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.